Incyte Corporation
Incyte Reports Strong 2023 Financial Results and Provides 2024 Guidance
Summary
Incyte Corporation reported its 2023 financial results on February 13, 2024, showing a 14% increase in total net product and royalty revenues to $3.7 billion. The company achieved a new milestone of $1 billion in total quarterly revenues for the first time, driven by the growth of Jakafi and the successful launch of Opzelura. For 2024, Incyte provided financial guidance, anticipating Jakafi net product revenues between $2,690 - $2,750 million. The company also announced updates on its research and development pipeline, highlighting advancements in high potential programs and the acquisition of exclusive global rights for tafasitamab.
Profitelligence Alerts
Get alerts for INCY
Be first to know when Incyte Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. With a focus on oncology and inflammation, Incyte aims to address significant unmet medical needs through its robust portfolio of proprietary compounds. The company's flagship product, a therapeutic for certain types of blood cancers, underscores its pivotal role in cancer treatment paradigms. Incyte also invests heavily in research and development, maintaining a pipeline of next-generation treatments in various stages of clinical trials. Having established strategic partnerships with leading global pharmaceutical companies, Incyte leverages collaborative efforts to enhance its research capabilities and market presence. Headquartered in Wilmington, Delaware, Incyte Corporation is a key player in the biopharmaceutical sector, significantly contributing to advancements in medical science and patient care through its commitment to innovation and therapeutic excellence.
Official SEC Documents
Advertisement